With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn’t overwhelm trial organizers.
The most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo’s semaglutide, which, if approved, could steal market share from Eli Lilly’s Trulicity.
The answer: it depends on what phase the trial is in.
There is a misperception in the U.S. that we have “conquered” heart disease and stroke, but the evidence shows that this is far from true.
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.
Please login or register first to view this content.
